A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias.

ABSTRACT: Low magnesium may increase the risk of atrial fibrillation. We conducted a double-blind pilot randomized trial to assess adherence to oral magnesium supplementation (400 mg of magnesium oxide daily) and a matching placebo, estimate the effect on circulating magnesium concentrations, and evaluate the feasibility of using an ambulatory heart rhythm monitoring device (ZioPatch) for assessing premature atrial contractions. A total of 59 participants were randomized; 73% were women, and the mean age was 62 years. A total of 98% of the participants completed the follow-up. In the magnesium supplement group, 75% of pills were taken, and in the placebo group, 83% were taken. The change in magnesium concentrations was significantly greater for those given the magnesium supplements than for those gi

SUBMITTER: Lutsey PL 

PROVIDER: S-EPMC6073799 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature